Success Metrics

Clinical Success Rate
75.0%

Based on 6 completed trials

Completion Rate
75%(6/8)
Active Trials
4(33%)
Results Posted
33%(2 trials)
Terminated
2(17%)

Phase Distribution

Ph phase_1
3
25%
Ph phase_2
6
50%

Phase Distribution

3

Early Stage

6

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
3(33.3%)
Phase 2Efficacy & side effects
6(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

4

trials recruiting

Total Trials

12

all time

Status Distribution
Active(4)
Completed(6)
Terminated(2)

Detailed Status

Completed6
Recruiting2
Terminated2
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
12
Active
4
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (33.3%)
Phase 26 (66.7%)

Trials by Status

recruiting217%
terminated217%
active_not_recruiting217%
completed650%

Recent Activity

4 active trials
Showing 5 of 12
recruitingphase_2

AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma

NCT05669339
active_not_recruitingphase_2

Tailored Sonidegib Schedule After Complete Response in BCC

NCT04806646
active_not_recruitingphase_1

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

NCT04007744
completed

Post-authorization Safety Study on the Long Term Safety of Sonidegib in Patients With Locally Advanced Cell Carcinoma

NCT04066504
completedphase_2

A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma

NCT03534947
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT05669339Phase 2

AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma

Recruiting
NCT04806646Phase 2

Tailored Sonidegib Schedule After Complete Response in BCC

Active Not Recruiting
NCT04007744Phase 1

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

Active Not Recruiting
NCT04066504

Post-authorization Safety Study on the Long Term Safety of Sonidegib in Patients With Locally Advanced Cell Carcinoma

Completed
NCT03534947Phase 2

A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma

Completed
NCT04402073Phase 2

Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma

Terminated
NCT07068568

Dose-Modulated Sonidegib Therapy for Periocular Basal Cell Carcinoma

Completed
NCT05463757

Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study

Recruiting
NCT03434262Phase 1

SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

Completed
NCT02086552Phase 2

Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed
NCT02129101Phase 1

Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies

Completed
NCT02303041Phase 2

Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma

Terminated

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12